Perspective
Volume 09:04, 2025

Reports in Thyroid Research

ISSN: 2684-4273

Open Access

FTC: Molecular Diagnostics, Prognosis, Therapy

Luis Fernando Rocha*

Department of Biochemistry Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Introduction

Follicular thyroid carcinoma (FTC) represents a significant area of focus within thyroid oncology, demanding a nuanced understanding of its various facets. An extensive overview of this condition delves into its epidemiology, molecular pathogenesis, and diagnostic challenges [1].

This includes exploring the roles of fine-needle aspiration cytology and advanced molecular testing, alongside a discussion of evolving treatment strategies like surgery, radioiodine therapy, and targeted approaches for advanced cases. The importance of accurate risk stratification and personalized management for improving patient outcomes is consistently emphasized [1].

Delving deeper, the molecular underpinnings of FTC are critical for precise diagnosis and tailored treatment. This involves understanding key genetic alterations, such as RAS mutations and PAX8/PPARG fusions, which are central to the disease's development [2].

Researchers often discuss the utility of various molecular biomarkers. These markers are instrumental in enhancing the diagnostic accuracy of indeterminate thyroid nodules, enabling clinicians to distinguish FTC from benign lesions effectively. Ultimately, these molecular insights help predict prognosis, thereby informing therapeutic decisions and guiding personalized medicine strategies [2].

Prognosis in FTC is heavily influenced by specific clinicopathological features. Retrospective studies analyzing patient data have identified several significant prognostic factors [3].

Notably, tumor size, the extent of capsular invasion, the presence of angioinvasion, and distant metastasis are independently linked with a poor prognosis and an elevated risk of recurrence. Such insights are invaluable for developing robust risk stratification models and planning individualized post-operative management strategies [3].

Diagnostic approaches continue to evolve, particularly concerning the limitations of traditional methods. Fine-needle aspiration cytology (FNAC), while useful, often falls short in definitively diagnosing FTC because it cannot reliably assess capsular or vascular invasion [4].

This inherent limitation has brought the increasing importance of molecular testing to the forefront. For indeterminate nodules, specifically those classified as Bethesda III/IV, molecular testing plays a crucial role in refining risk stratification, reducing the incidence of unnecessary surgeries, and improving overall diagnostic accuracy. This shift helps guide clinical decisions toward more personalized patient management [4].

Surgical interventions are a cornerstone of FTC treatment, with a focus on optimizing patient outcomes. A systematic review and meta-analysis of surgical approaches discusses the extent of thyroidectomy required [5].

It highlights the clear benefits of total thyroidectomy, particularly for high-risk patients, as it effectively reduces recurrence risk and facilitates subsequent radioiodine therapy. This body of evidence provides crucial, data-driven guidance for surgical decision-making, aiming to maximize therapeutic efficacy while minimizing potential complications [5].

Special considerations are necessary when FTC affects younger populations. A dedicated study examines the characteristics and outcomes of FTC in pediatric and adolescent patients [6].

While FTC is considered rare in these age groups, it frequently presents with a more advanced stage of disease at diagnosis compared to adult patients. Despite this, the prognosis is generally favorable following aggressive surgical intervention and radioiodine management. These findings underscore a distinct need for specialized care and long-term surveillance protocols tailored for younger patients [6].

Radioiodine therapy (RAI) holds a crucial position in the multimodal management of FTC. A comprehensive review article details the current indications and efficacy of RAI [7].

It emphasizes RAI's vital role in ablating any remnant thyroid tissue after surgery, effectively treating distant metastases, and improving disease-free survival, especially for patients categorized as intermediate- or high-risk. The discussion also encompasses important aspects such as patient preparation, ongoing controversies surrounding its application in low-risk disease, and strategies aimed at minimizing potential side effects [7].

For cases of advanced FTC, understanding the molecular landscape is paramount for developing effective targeted therapies. Reviews explore the molecular profile of advanced FTC, drawing attention to prevalent mutations such as RAS, PAX8/PPARG, and TERT promoter mutations [8].

These specific genetic alterations are known to drive aggressive disease behavior and contribute to radioiodine refractoriness. Consequently, the potential of targeted therapies, including multi-kinase inhibitors, to improve outcomes in patients with advanced, metastatic, or RAI-refractory FTC by directly addressing these molecular alterations is a significant area of research and clinical development [8].

Standardized guidelines are essential for consistent and effective patient care. Comprehensive guidelines provide recommendations for the diagnosis and management of differentiated thyroid cancer (DTC), which includes FTC [9].

These guidelines cover various critical aspects, such as risk stratification, deter-

mining the appropriate extent of surgery, indications for radioiodine therapy, the role of TSH suppression, and effective surveillance strategies. The overarching goal is to standardize optimal care based on the most recent evidence and clinical expertise, ultimately aiming to improve patient outcomes across the entire spectrum of DTC [9].

Finally, evolving diagnostic classifications also impact FTC management. A key update addresses Non-invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) [10].

This entity has been reclassified from a variant of papillary thyroid carcinoma to a distinct category with exceedingly low malignant potential. The article details the precise diagnostic criteria for NIFTP and clarifies its differentiation from true follicular thyroid carcinoma and invasive follicular variant of papillary thyroid carcinoma. This reclassification is crucial as it helps prevent overtreatment, thereby reducing unnecessary interventions and alleviating patient anxiety [10].

Description

Follicular thyroid carcinoma (FTC) is a multifaceted malignancy requiring sophisticated diagnostic and management strategies to improve patient outcomes. A comprehensive understanding begins with its epidemiology, molecular pathogenesis, and the complex diagnostic challenges inherent to the disease [1]. Contemporary approaches emphasize the crucial role of fine-needle aspiration cytology (FNAC) and advanced molecular testing, alongside evolving treatment modalities that span surgery, radioiodine therapy (RAI), and targeted therapies for advanced stages [1]. Crucially, accurate risk stratification and personalized management are paramount for optimizing patient prognosis and guiding treatment choices from initial diagnosis through long-term surveillance [1].

The molecular landscape of FTC is pivotal for both precise diagnosis and effective therapeutic targeting. Specific genetic alterations, notably RAS mutations and PAX8/PPARG fusions, represent key molecular underpinnings driving this carcinoma, influencing its development and progression [2]. These genetic insights are not merely academic; they translate into practical molecular biomarkers that significantly enhance the diagnostic accuracy of indeterminate thyroid nodules, helping to discern FTC from benign lesions with greater certainty [2]. Furthermore, these biomarkers contribute to predicting the disease's prognosis, thereby directly influencing therapeutic decisions and fostering highly personalized medicine strategies [2]. For advanced cases, the molecular profile, including prevalent mutations like RAS, PAX8/PPARG, and TERT promoter, is thoroughly explored, as these often drive aggressive disease behavior and lead to radioiodine refractoriness. This understanding is critical for exploring and applying targeted therapies, such as multi-kinase inhibitors, that can specifically address these molecular alterations and improve outcomes [8].

Diagnosing FTC presents distinct challenges, particularly with conventional methods. FNAC, while widely used, has inherent limitations because it cannot definitively assess capsular or vascular invasion—features critical for distinguishing benign from malignant follicular lesions [4]. This diagnostic gap underscores the growing importance of molecular testing for indeterminate nodules, especially those classified as Bethesda III/IV. Such testing refines risk stratification, helps avoid unnecessary diagnostic surgeries, and substantially improves overall diagnostic precision, thereby guiding clinical decisions towards truly individualized patient management [4]. Moreover, evolving classifications significantly impact diagnostic clarity. Non-invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) has been reclassified from a variant of papillary thyroid carcinoma to a distinct entity with exceedingly low malignant potential [10]. This reclassification details specific diagnostic criteria for NIFTP and clarifies its differentiation from true follicular thyroid carcinoma and invasive follicular variant, ultimately preventing overtreatment and alleviating patient anxiety [10].

Prognostic factors are essential for tailoring effective treatment and surveillance plans. Retrospective analyses involving large patient cohorts have clearly highlighted that factors such as tumor size, extensive capsular invasion, angioinvasion, and distant metastasis are independently associated with a poor prognosis and an increased recurrence risk [3]. These findings provide critical insights for robust risk stratification, guiding individualized post-operative management tailored to each patient's specific risk profile [3]. When considering definitive treatment, surgical approaches are meticulously evaluated. A systematic review and meta-analysis of surgical management for FTC has shown that total thyroidectomy, particularly for high-risk patients, proves highly beneficial in reducing recurrence risk and facilitating subsequent radioiodine therapy [5]. Comprehensive guidelines further standardize optimal care for differentiated thyroid cancer, including FTC, covering crucial aspects such as risk stratification, the appropriate extent of surgery, clear indications for radioiodine therapy, TSH suppression strategies, and long-term surveillance protocols, all based on the latest evidence and clinical expertise [9].

Radioiodine therapy (RAI) plays a central and often crucial role in managing FTC, especially in specific patient cohorts. Its current indications and efficacy are well-documented, emphasizing its vital role in ablating remnant thyroid tissue post-surgery, effectively treating distant metastases, and significantly improving disease-free survival, particularly for intermediate- and high-risk patients [7]. Considerations for patient preparation, ongoing discussions regarding its utility in low-risk disease, and strategies to mitigate potential side effects are all important aspects of its clinical application [7]. Furthermore, specific patient populations, such as pediatric and adolescent patients, require specialized and tailored care. Though FTC is rare in younger individuals, studies indicate it often presents with more advanced disease at diagnosis compared to adults [6]. Encouragingly, it generally carries a favorable prognosis when managed with aggressive surgical and radioiodine interventions, underscoring the necessity for specialized multidisciplinary care and diligent long-term surveillance in this particular demographic [6].

Conclusion

Follicular thyroid carcinoma (FTC) necessitates comprehensive diagnostic and therapeutic strategies. Research highlights the disease's epidemiology, molecular pathogenesis, and evolving treatment modalities, stressing personalized management and accurate risk stratification [1]. Key molecular underpinnings include RAS mutations and PAX8/PPARG fusions, which serve as crucial diagnostic and prognostic biomarkers for distinguishing FTC from benign lesions and guiding therapy [2]. Prognostic factors like tumor size, extensive capsular invasion, angioinvasion, and distant metastasis are significant predictors of poor outcomes [3]. While fine-needle aspiration cytology (FNAC) has diagnostic limitations, molecular testing for indeterminate thyroid nodules is increasingly vital for refining risk and reducing unnecessary surgeries [4]. Surgical management often involves total thyroidectomy, especially for high-risk patients, to decrease recurrence and facilitate radioiodine therapy (RAI) [5]. RAI itself is critical for ablating remnant tissue, treating distant metastases, and improving disease-free survival in intermediate- and high-risk patients [7]. For advanced or RAI-refractory FTC, molecular profiling reveals mutations like RAS, PAX8/PPARG, and TERT promoter, paving the way for targeted therapies using multi-kinase inhibitors [8]. Management guidelines integrate risk stratification, surgery, RAI indications, TSH suppression, and surveillance for differentiated thyroid cancer, including FTC, to standardize care [9]. Moreover, Non-invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP)

has been reclassified as a distinct entity with low malignant potential, differentiating it from true FTC and preventing overtreatment [10]. Special considerations exist for pediatric and adolescent patients, where FTC, though rare, often presents at an advanced stage but typically carries a favorable prognosis with aggressive management [6].

Acknowledgement

None.

Conflict of Interest

None.

References

1. Yu-Hsin Lu, Chieh-Hsin Li, Mei-Chen Huang. "Follicular Thyroid Carcinoma: Diagnostic, Prognostic, and Therapeutic Aspects." *Cancers* (Basel) 15 (2023):1761.
2. Peng-Fei Zhang, Jie-Fu Chen, Dong-Hong Cai. "Molecular Pathogenesis and Diagnostic Biomarkers of Follicular Thyroid Carcinoma: A Review of Recent Advances." *Front Oncol* 11 (2021):746405.
3. Qian Gao, Lin Meng, Lu-Lu Wu. "Clinicopathological Characteristics and Prognostic Factors of Follicular Thyroid Carcinoma: *A Retrospective Analysis of* 452 Patients." World J Surg 44 (2020):2686-2693.
4. Cristina Saggiorato, Irene Campello, Alessandro Prete. "The Role of Fine Needle Aspiration Cytology and Molecular Testing in the Diagnosis of Follicular Thyroid Carcinoma." *Cancers* (Basel) 14 (2022):1761.
5. Min-Ho Kim, Hyun-Seok Kim, Tae-You Kim. "Surgical management of follicular thyroid carcinoma: A systematic review and meta-analysis." *World J Surg Oncol* 19 (2021):173.
6. Yael Schwartz, Sharon Perlman, David Golzman. "Follicular Thyroid Carcinoma in Children and Adolescents: A Single-Institution Experience." *J Clin Endocrinol Metab* 105 (2020):dgaa468.
7. Jae Sung Yun, Tae Sung Kim, Byung Joo Kim. "The Role of Radioiodine Therapy in Follicular Thyroid Carcinoma: A Current Perspective." *Cancers* (Basel) 13 (2021):3816.
8. Manuela L. Capdevila, Laura P. Montiel, Maria S. Zafra. "Molecular Landscape of Advanced Follicular Thyroid Carcinoma: Implications for Targeted Therapy." *Cancers* (Basel) 12 (2020):3317.
9. Dong-Jun Lim, Chan-Kwon Jung, Young Joo Park. "Guideline for the Management of Differentiated Thyroid Cancer in Adults: Korean Thyroid Association Recommendation." *J Korean Med Sci* 36 (2021):e150.
10. Juan C. Hernandez-Prera, Yuri E. Nikiforov, Justin A. Bishop. "Non-invasive Follicular Thyroid Neoplasm with Papillary-Like *Nuclear Features* (NIFTP): Updates and Future Perspectives." Semin Diagn Pathol 37 (2020):200-205.

How to cite this article: Rocha, Luis Fernando. "FTC: Molecular Diagnostics, Prognosis, Therapy." *Rep Thyroid Res* 09 (2025):136.

Address for Correspondence: Luis, Fernando Rocha, Department of Biochemistry Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, E-mail: l.rocha@ufrj.br

Received: 02-Dec-2025, Manuscript No. rtr-25-173566; **Editor assigned:** 04-Dec-2025, PreQC No. P-173566; **Reviewed:** 18-Dec-2025, QC No. Q-173566; **Revised:** 23-Dec-2025, Manuscript No. R-173566; **Published:** 30-Dec-2025, DOI: 10.37421/2684-4273.2025.9.136